DNLI
Denali Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
Market Cap: 2.86 Billion
Primary Exchange: NASDAQ
Website: https://www.denalitherapeutics.com
Shares Outstanding: 139 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.82216897196745
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 1054 trading days
From: 2020-12-22 To: 2024-03-07
Lowest Point:
Prevail Therapeutics Proposes IPO Terms
via: SeekingAlpha at 2019-06-13 07:46:25:000
Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases… read more...
Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer
via: SeekingAlpha at 2019-06-12 08:10:47:000
Shares of Denali Therapeutics ( DNLI ) have risen by only 5% since its December 2017 IPO was priced at $18 per share. Year to date, the stock is in the red by about 8%. Given my rekindled interest in the Parkinson space and desire to have more names on the radar that could achieve proof of… read more...
Denali's DNL310 nabs accelerated review status in U.S. for MPS II
via: SeekingAlpha at 2019-06-11 06:58:30:000
The FDA grants Orphan Drug and Rare Pediatric Disease Designation status to Denali Therapeutics' ( DNLI +0.6% ) DNL310 for the treatment of mucopolysaccharidosis II (MPS II), also known as Hunter syndrome , a rare inherited disorder characterized by a large head, excess fluid in the bra… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|